<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843531</url>
  </required_header>
  <id_info>
    <org_study_id>084511</org_study_id>
    <secondary_id>NCI-2011-01291</secondary_id>
    <nct_id>NCT00843531</nct_id>
  </id_info>
  <brief_title>RAD001 and Erlotinib in Patients With Neuroendocrine Tumors</brief_title>
  <official_title>A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The V Foundation for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test how safe and effective the combination of RAD001 and&#xD;
      erlotinib is in patients with neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical data suggest that concomitant inhibition of two non-redundant amplified pathways&#xD;
      (mTOR and EGFR) can reverse drug resistance and more profoundly affect tumor growth than&#xD;
      targeting either pathway alone. EGFR inhibitors may abrogate feedback loops that stimulate&#xD;
      upstream signaling events such as PI3K and Akt in the face of mTOR inhibition. Although ErbB&#xD;
      receptors signal through mTOR-dependent mechanisms, mTOR-independent ErbB receptor signaling&#xD;
      also occurs in cancer. Furthermore, deregulation of apoptotic pathways like the PI3K/Akt/PTEN&#xD;
      axis (e.g. via PTEN loss of function or AKT gene amplification) may lead to resistance to&#xD;
      EGFR inhibitors. Treatment with an inhibitor of mTOR may reverse this resistance. Targeting&#xD;
      the mTOR and EGFR pathways concurrently may more effectively inhibit tumor growth than&#xD;
      inhibiting either pathway alone.&#xD;
&#xD;
      The compelling preclinical data, coupled with modest single agent activity seen with EGFR&#xD;
      inhibition and mTOR inhibition in neuroendocrine tumors (NETs), provides a strong rationale&#xD;
      for studying the activity of concomitant pathway inhibition in patients with advanced NETs.&#xD;
      Support for this strategy also stems from the fact that EGFR inhibitors can be safety&#xD;
      combined with mTOR inhibitors in humans. Emerging data from a phase I study of RAD001 plus&#xD;
      erlotinib in patients with previously treated advanced non-small cell lung cancer (NSCLC)&#xD;
      suggests that the two agents can be safely combined at the following doses: RAD001 5 mg PO q&#xD;
      D and erlotinib 150 mg PO qD.&#xD;
&#xD;
      Of note, the original dose selections for RAD001 and erlotinib for this study stem directly&#xD;
      from phase I studies with this combination (RAD001 5 mg PO qD plus erlotinib 150 mg PO qD).&#xD;
      The modified dose selections (RAD001 5 mg PO qD plus erlotinib 100 mg PO qD) are the result&#xD;
      of integrating discussions with the study sponsor, preliminary safety data from the first few&#xD;
      patients enrolled in this study (suggesting that some patients tolerate full-dose therapy and&#xD;
      others do not) and additional phase I data suggesting that the maximum tolerated dose (MTD)&#xD;
      in some patient populations is lower than in others, e.g. the MTD in breast cancer patients&#xD;
      is RAD001 2.5 mg PO qD and erlotinib 100 mg PO QD (Mayer et al. American Society of Clinical&#xD;
      Oncology (ASCO) 2009 Breast Cancer Symposium, Abstract #254).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 25, 2009</start_date>
  <completion_date type="Actual">August 20, 2016</completion_date>
  <primary_completion_date type="Actual">July 16, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective response is defined as complete response (CR) or partial response (PR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The primary analysis population is based on efficacy-evaluable patients, defined as those patients who receive at least one cycle of RAD001 plus erlotinib and undergo at least one post-baseline response assessment or die while on therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Primary safety analysis will be conducted after the first 16 patients have had potential for completion of two cycles of protocol therapy. All patients receiving at least one dose of protocol therapy will be included in the analyses. All patients with treatment-related, Grade 3 or higher adverse events according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 resulting in a DLT will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of objective response will be defined as the time from the initial documentation of response to documented disease progression or death from any cause on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Overall survival will be defined as the time from first day of treatment until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>PFS will be defined as the time from the first day of treatment and documented objective response to time of progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to treatment failure will be defined as the time from first day of treatment until study discontinuation (for any cause).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>RAD001 and erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each 28 day cycle:&#xD;
RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>5 mg/day PO (oral)</description>
    <arm_group_label>RAD001 and erlotinib</arm_group_label>
    <other_name>Everolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>100 mg/day (oral)</description>
    <arm_group_label>RAD001 and erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;=1 measurable disease site per RECIST, not previously irradiated (if previous&#xD;
             radiation to marker lesion(s), need evidence of PD)&#xD;
&#xD;
          -  Histologic dx of well- to moderately-differentiated NET: low- or intermediate-grade,&#xD;
             islet cell carcinoma, pancreatic NET, carcinoid, atypical carcinoid, paraganglioma,&#xD;
             pheochromocytoma. No longer enrolling carcinoid patients as of 4/25/2011.&#xD;
&#xD;
          -  ≥4 wks since completion of prior investigational drug tx or other tx(radiation,&#xD;
             chemotherapy, immunotherapy, antibody-based tx); recovery from acute toxicities of&#xD;
             prior tx&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) ≤2&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥1500/μL&#xD;
&#xD;
          -  Plts ≥100,000/μL&#xD;
&#xD;
          -  Hgb &gt;9 gm/dL&#xD;
&#xD;
          -  Total bilirubin ≤2.0 mg/dL or 1.5X upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum transaminases ≤2.5x ULN (≤5xULN if liver mets)&#xD;
&#xD;
          -  Serum Cr ≤2.0 mg/dL or 1.5X ULN&#xD;
&#xD;
          -  Fasting serum glucose &lt;150 mg/dL or &lt;1.5x ULN&#xD;
&#xD;
          -  Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides&#xD;
             ≤2.5xULN&#xD;
&#xD;
          -  International Normalized Ratio (INR) ≤1.5&#xD;
&#xD;
          -  Written informed consent, compliance w/study requirements&#xD;
&#xD;
          -  Archived tissue if available&#xD;
&#xD;
          -  Negative urine/serum pregnancy test w/in 7 days prior to Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poorly differentiated NET, high-grade NET, adenocarcinoid, goblet cell carcinoid,&#xD;
             small cell carcinoma&#xD;
&#xD;
          -  Major surgery or traumatic injury w/in 4 wks, inadequate recovery from side effects of&#xD;
             any surgery, or likely to require major surgery during study&#xD;
&#xD;
          -  Liver-directed therapy w/in 2 mths of enrollment. Prior tx w/ radiotherapy (including&#xD;
             radiolabeled spheres, cyberknife, hepatic arterial embolization (w/ or w/o&#xD;
             chemotherapy), cryotherapy/ablation) allowed if areas of measurable disease being used&#xD;
             for the study are not affected, or if PD can clearly be documented in the area&#xD;
&#xD;
          -  Prior tx w/ EGFR inhibitor or mTOR inhibitor&#xD;
&#xD;
          -  Known hypersensitivity to RAD001 or other rapamycins&#xD;
&#xD;
          -  Chronic, systemic tx w/ corticosteroids or another immunosuppressive agent (topical or&#xD;
             inhaled corticosteroids are allowed)&#xD;
&#xD;
          -  Immunization w/ attenuated live vaccines w/in 1 wk of study entry or during study&#xD;
&#xD;
          -  Uncontrolled brain or leptomeningeal mets, including pts who continue to require&#xD;
             glucocorticoids for brain or leptomeningeal mets&#xD;
&#xD;
          -  Other malignancies w/in the past 3 years except for adequately treated carcinoma of&#xD;
             the cervix, basal/squamous cell skin carcinomas, or other in situ cancer&#xD;
&#xD;
          -  Severe and/or uncontrolled intercurrent medical conditions or other conditions that&#xD;
             may affect study participation, including, but not limited to:&#xD;
&#xD;
          -  Severely impaired lung function (spirometry and Diffusing capacity of the lungs for&#xD;
             carbon monoxide (DLCO) that is 50% of the normal predicted value and/or O2 saturation&#xD;
             ≤88% at rest on room air)&#xD;
&#xD;
          -  Symptomatic congestive heart failure (CHF) of New York Heart Association (NYHA) Class&#xD;
             III or IV&#xD;
&#xD;
          -  Unstable angina pectoris, symptomatic CHF, myocardial infarction w/in 6 months of Day&#xD;
             1, uncontrolled cardiac arrhythmia or any other significant cardiac disease&#xD;
&#xD;
          -  Uncontrolled diabetes (fasting serum glucose ≥ 150 mg/dL or &gt;1.5x upper limit of&#xD;
             normal (ULN))&#xD;
&#xD;
          -  Any active (acute or chronic) or severe infection, disorder, or nonmalignant medical&#xD;
             illness that is uncontrolled or whose control may be jeopardized by study tx&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Hx of HIV seropositivity or other immunocompromised state&#xD;
&#xD;
          -  GI function impairment or disease that may alter absorption of RAD001 or erlotinib&#xD;
&#xD;
          -  Active, bleeding diathesis or on oral anti-vitamin K medication (patients needing&#xD;
             anticoagulation must use low molecular weight heparin (LMWH))&#xD;
&#xD;
          -  Hx of other disease, metabolic dysfunction, or physical exam or lab finding giving&#xD;
             reasonable suspicion of disease/condition that contraindicates study tx, might affect&#xD;
             study results or puts the pt at high risk&#xD;
&#xD;
          -  Pregnant or breast feeding females&#xD;
&#xD;
          -  Adults of reproductive potential not willing to use effective methods of birth control&#xD;
             during tx and ≥8 wks after completing tx&#xD;
&#xD;
          -  Inability to comply w/ objectives and procedures&#xD;
&#xD;
          -  Inability to comply w/ concomitant medication restrictions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily K. Bergsland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <results_first_submitted>August 29, 2020</results_first_submitted>
  <results_first_submitted_qc>September 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2020</results_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Emily Bergsland</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>neuroendocrine</keyword>
  <keyword>islet cell</keyword>
  <keyword>carcinoid</keyword>
  <keyword>pancreatic neuroendocrine</keyword>
  <keyword>paraganglioma</keyword>
  <keyword>pheochromocytoma</keyword>
  <keyword>RAD001</keyword>
  <keyword>everolimus</keyword>
  <keyword>erlotinib</keyword>
  <keyword>Tarceva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RAD001 and Erlotinib</title>
          <description>RAD001 and erlotinib&#xD;
Each 28 day cycle:&#xD;
RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RAD001 and Erlotinib</title>
          <description>everolimus 5 mg daily and continued this throughout the duration of treatment&#xD;
erlotinib at a dose of 100 mg daily with the option to dose reduce erlotinib to 100 mg daily in the setting of grade 3/4 rash or diarrhea&#xD;
cycles defined as every 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Neuroendocrine Tumor Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Carcinoid Neuroendocrine Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic neuroendocrine tumor (PNET)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Objective response is defined as complete response (CR) or partial response (PR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The primary analysis population is based on efficacy-evaluable patients, defined as those patients who receive at least one cycle of RAD001 plus erlotinib and undergo at least one post-baseline response assessment or die while on therapy.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAD001 Plus Erlotinib</title>
            <description>everolimus 5 mg daily and continued this throughout the duration of treatment&#xD;
erlotinib at a dose of 100 mg daily with the option to dose reduce erlotinib to 100 mg daily in the setting of grade 3/4 rash or diarrhea&#xD;
cycles defined as every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Objective response is defined as complete response (CR) or partial response (PR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The primary analysis population is based on efficacy-evaluable patients, defined as those patients who receive at least one cycle of RAD001 plus erlotinib and undergo at least one post-baseline response assessment or die while on therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Dose-limiting Toxicity (DLT)</title>
        <description>Primary safety analysis will be conducted after the first 16 patients have had potential for completion of two cycles of protocol therapy. All patients receiving at least one dose of protocol therapy will be included in the analyses. All patients with treatment-related, Grade 3 or higher adverse events according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 resulting in a DLT will be reported.</description>
        <time_frame>Up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAD001 and Erlotinib</title>
            <description>Each 28 day cycle:&#xD;
RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)&#xD;
RAD001: 5 mg/day PO (oral)&#xD;
erlotinib: 100 mg/day (oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Dose-limiting Toxicity (DLT)</title>
          <description>Primary safety analysis will be conducted after the first 16 patients have had potential for completion of two cycles of protocol therapy. All patients receiving at least one dose of protocol therapy will be included in the analyses. All patients with treatment-related, Grade 3 or higher adverse events according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 resulting in a DLT will be reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Response</title>
        <description>Duration of objective response will be defined as the time from the initial documentation of response to documented disease progression or death from any cause on study</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAD001 and Erlotinib</title>
            <description>RAD001 and erlotinib&#xD;
Each 28 day cycle:&#xD;
RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Objective Response</title>
          <description>Duration of objective response will be defined as the time from the initial documentation of response to documented disease progression or death from any cause on study</description>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants obtained an objective response</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival will be defined as the time from first day of treatment until death</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data for overall survival not collected</population>
        <group_list>
          <group group_id="O1">
            <title>RAD001 and Erlotinib</title>
            <description>RAD001 and erlotinib&#xD;
Each 28 day cycle:&#xD;
RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival will be defined as the time from first day of treatment until death</description>
          <population>Data for overall survival not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-Free Survival (PFS)</title>
        <description>PFS will be defined as the time from the first day of treatment and documented objective response to time of progression or death from any cause, whichever occurs first</description>
        <time_frame>Up to 3 years</time_frame>
        <population>No participants obtained an objective response (CR or PR) therefore data for long term progression-free survival data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>RAD001 and Erlotinib</title>
            <description>RAD001 and erlotinib&#xD;
Each 28 day cycle:&#xD;
RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival (PFS)</title>
          <description>PFS will be defined as the time from the first day of treatment and documented objective response to time of progression or death from any cause, whichever occurs first</description>
          <population>No participants obtained an objective response (CR or PR) therefore data for long term progression-free survival data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first).</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data for time to progression not collected</population>
        <group_list>
          <group group_id="O1">
            <title>RAD001 Plus Erlotinib</title>
            <description>RAD001 and erlotinib&#xD;
Each 28 day cycle:&#xD;
RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first).</description>
          <population>Data for time to progression not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF)</title>
        <description>Time to treatment failure will be defined as the time from first day of treatment until study discontinuation (for any cause).</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data for time to treatment failure not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Carcinoid Tumors</title>
            <description>everolimus 5 mg daily and continued this throughout the duration of treatment&#xD;
erlotinib at a dose of 100 mg daily with the option to dose reduce erlotinib to 100 mg daily in the setting of grade 3/4 rash or diarrhea&#xD;
cycles defined as every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF)</title>
          <description>Time to treatment failure will be defined as the time from first day of treatment until study discontinuation (for any cause).</description>
          <population>Data for time to treatment failure not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RAD001 Plus Erlotinib</title>
          <description>everolimus 5 mg daily and continued this throughout the duration of treatment&#xD;
erlotinib at a dose of 100 mg daily with the option to dose reduce erlotinib to 100 mg daily in the setting of grade 3/4 rash or diarrhea&#xD;
cycles defined as every 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - Other - Right upper quadrant pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="13" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="15" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypercholesteremia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Nose</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="24" subjects_affected="11" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated earlier than expected due to insufficient efficacy at interim analysis and overall low enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Emily Bergsland, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 514-6520</phone>
      <email>Emily.Bergsland@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

